ReviewInflammatory bowel diseases2026
Trained immunity: An unexplored component of IBD pathogenesis.
Review in Inflammatory bowel diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trained immunity (TI) describes the capability of the innate immune system and its tissue-resident cells to acquire long-lasting functional adaptations following an initial inflammatory or microbial insult. These changes are maintained through coordinated immunometabolic rewiring and epigenetic remodeling, resulting in amplified or altered responses upon subsequent challenges. Inflammatory bowel disease (IBD) is a chronic, relapsing disorder of the gastrointestinal tract, and TI offers a useful framework for understanding disease persistence, relapse proneness, and incomplete resolution despite effective targeting of adaptive immune pathways. While TI has been extensively studies in various chronic inflammatory disorders, its role in IBD remains rather underexplored and largely confined to early preclinical evidence. Within this narrative review, we aim to address this gap by providing current insights into the potential pathogenetic mechanisms underpinning TI in IBD. We examine how the shaping of the behavior of monocytes, macrophages, and their bone marrow progenitors and how steady exposure to microbial ligands, dysbiotic metabolites, and metabolic stressors within the intestinal lumen may establish a sustained proinflammatory "memory" in the context of IBD. From a translational perspective, we consider how TI may favor relapse even during clinical remission and discuss its potential relevance for patient stratification, biomarker identification, and the development of novel therapeutic strategies. Ultimately, integration of TI into IBD pathophysiology may corroborate more lasting, mechanism-based approaches to remission.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.